Literature DB >> 17460450

The expression of transforming growth factor-alpha in cirrhosis, dysplastic nodules, and hepatocellular carcinoma: an immunohistochemical study of 70 cases.

Matthew M Yeh1, Anne M Larson, Jean S Campbell, Nelson Fausto, Stephen J Rulyak, Paul E Swanson.   

Abstract

The emergence of hepatocellular carcinoma (HCC) is thought to be a stepwise process, with high-grade dysplastic nodules (HGDN) representing premalignant lesions arising in a background of cirrhosis. Earlier studies have revealed altered expression of transforming growth factor-alpha (TGF-alpha) (a mitogen capable of inducing hepatocarcinogenesis in mice) in HCC and its surrounding parenchyma. DNA topoisomerase II-alpha (Topo II-alpha) is a nuclear protein targeted by several chemotherapeutic agents and is overexpressed in HCC. The expression of both TGF-alpha and Topo II-alpha in putative preneoplastic hepatocytic lesions, however, has not been extensively studied. We examined the patterns of TGF-alpha and Topo II-alpha expression in noncirrhotic liver, liver cirrhosis, low-grade dysplastic nodules (LGDN), HGDN, and HCC to define the possible relationships of these markers to tumor progression. Paraffin sections from formalin-fixed material were immunostained with antibodies against TGF-alpha, Topo II-alpha, and Ki-67. Forty-six HCC, 17 HGDN, and 12 low-grade dysplastic nodules were identified in 52 cirrhotic livers from explanted or resected specimens. Nuclear staining for Ki-67 and Topo II-alpha was significantly increased in the progression from cirrhosis, through HGDN, to HCC, whereas the scores for TGF-alpha in these lesions showed an inverse relationship. In comparison with 18 HCC arising in noncirrhotic livers, the expression of TGF-alpha is significantly stronger in cirrhotic liver than in noncirrhotic parenchyma and its expression is also stronger in HCC arising in cirrhosis than in HCC arising in noncirrhotic parenchyma. The increased expression of Topo II-alpha and Ki-67 from HGDN to HCC, when compared with cirrhosis, suggests that HGDN is a precursor lesion in hepatocarcinogenesis. The inverse relationship between these proliferative markers and TGF-alpha expression in these lesions and stronger expression of TGF-alpha in HCC arising in cirrhosis suggest that TGF-alpha may play an important role in the early events of liver carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17460450     DOI: 10.1097/PAS.0b013e31802ff7aa

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  5 in total

1.  TGF-beta inactivation and TGF-alpha overexpression cooperate in an in vivo mouse model to induce hepatocellular carcinoma that recapitulates molecular features of human liver cancer.

Authors:  Ji Yeon Baek; Shelli M Morris; Jean Campbell; Nelson Fausto; Matthew M Yeh; William M Grady
Journal:  Int J Cancer       Date:  2010-09-01       Impact factor: 7.396

2.  LAPTM4B-35 overexpression is a risk factor for tumor recurrence and poor prognosis in hepatocellular carcinoma.

Authors:  Hua Yang; Fu Xia Xiong; Ming Lin; Yu Yang; Xiu Nie; Rou Li Zhou
Journal:  J Cancer Res Clin Oncol       Date:  2009-08-19       Impact factor: 4.553

3.  Urinary transforming growth factor α and serum α-fetoprotein as tumor markers of hepatocellular carcinoma.

Authors:  Jen-Eing Jeng; Meng-Feng Tsai; Hey-Ru Tsai; Lea-Yea Chuang; Zu-Yau Lin; Min-Yuh Hsieh; Shinn-Chern Chen; Wan-Lung Chuang; Liang-Yen Wang; Min-Lung Yu; Chia-Yen Dai; Jung-Fa Tsai
Journal:  Tumour Biol       Date:  2013-12-30

4.  Biopsies of hepatocellular carcinoma with no reticulin loss: an important diagnostic pitfall.

Authors:  Saba Yasir; Zongming Eric Chen; Samar Said; Tsung-Teh Wu; Michael Torbenson
Journal:  Hum Pathol       Date:  2020-10-08       Impact factor: 3.526

5.  Activation of platelet-derived growth factor receptor alpha contributes to liver fibrosis.

Authors:  Brian J Hayes; Kimberly J Riehle; Masami Shimizu-Albergine; Renay L Bauer; Kelly L Hudkins; Fredrik Johansson; Matthew M Yeh; William M Mahoney; Raymond S Yeung; Jean S Campbell
Journal:  PLoS One       Date:  2014-03-25       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.